Published in Brain on May 04, 2012
B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol (2012) 1.80
Inflammation in neurodegenerative diseases--an update. Immunology (2014) 1.30
Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton. Neurol Neuroimmunol Neuroinflamm (2014) 1.20
B cells in MS and NMO: pathogenesis and therapy. Semin Immunopathol (2014) 1.01
The node of Ranvier in CNS pathology. Acta Neuropathol (2014) 0.97
Neuro-glial interactions at the nodes of Ranvier: implication in health and diseases. Front Cell Neurosci (2013) 0.94
Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid cause demyelination of spinal cord explants. Acta Neuropathol (2015) 0.85
Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. Neurol Neuroimmunol Neuroinflamm (2015) 0.85
B Cells in the Multiple Sclerosis Central Nervous System: Trafficking and Contribution to CNS-Compartmentalized Inflammation. Front Immunol (2015) 0.84
B Cells and Autoantibodies in Multiple Sclerosis. Int J Mol Sci (2015) 0.83
Anoctamin 2 identified as an autoimmune target in multiple sclerosis. Proc Natl Acad Sci U S A (2016) 0.82
B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions. Front Immunol (2015) 0.81
Transcript profiling of different types of multiple sclerosis lesions yields FGF1 as a promoter of remyelination. Acta Neuropathol Commun (2014) 0.79
The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis. Prog Neurobiol (2015) 0.79
A Distinct Class of Antibodies May Be an Indicator of Gray Matter Autoimmunity in Early and Established Relapsing Remitting Multiple Sclerosis Patients. ASN Neuro (2015) 0.78
Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid. J Neuroinflammation (2015) 0.78
Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments. Mult Scler Int (2015) 0.77
Maternal neurofascin-specific autoantibodies bind to structures of the fetal nervous system during pregnancy, but have no long term effect on development in the rat. PLoS One (2014) 0.77
A molecular view of multiple sclerosis and experimental autoimmune encephalitis: what can we learn from the epitope data? J Neuroimmunol (2013) 0.76
Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis. Neuropsychiatr Dis Treat (2015) 0.76
Hypersensitivity Responses in the Central Nervous System. Front Immunol (2015) 0.75
Is cerebral glucose metabolism related to blood-brain barrier dysfunction and intrathecal IgG synthesis in Alzheimer disease?: A 18F-FDG PET/CT study. Medicine (Baltimore) (2016) 0.75
Quantified CSF antibody reactivity against myelin in multiple sclerosis. Ann Clin Transl Neurol (2015) 0.75
Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination. Neurol Neuroimmunol Neuroinflamm (2016) 0.75
MOG-induced experimental autoimmune encephalomyelitis in the rat species triggers anti-neurofascin antibody response that is genetically regulated. J Neuroinflammation (2015) 0.75
Role of IL-33 and ST2 signalling pathway in multiple sclerosis: expression by oligodendrocytes and inhibition of myelination in central nervous system. Acta Neuropathol Commun (2016) 0.75
Peripheral VH4+ plasmablasts demonstrate autoreactive B cell expansion toward brain antigens in early multiple sclerosis patients. Acta Neuropathol (2016) 0.75
Neurofilament Light as an Immune Target for Pathogenic Antibodies. Immunology (2017) 0.75
New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol (1983) 26.67
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet (2004) 13.18
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med (2008) 12.90
Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol (2000) 9.73
Immunology of multiple sclerosis. Annu Rev Immunol (2005) 9.08
Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology (1976) 4.93
Myelination in rat brain: method of myelin isolation. J Neurochem (1973) 4.01
Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol (2009) 3.91
Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med (1999) 3.66
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol (2009) 3.35
AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol (2010) 3.28
Multiple sclerosis: a two-stage disease. Nat Immunol (2001) 3.20
Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol (1998) 2.97
Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol (1988) 2.93
Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet (2005) 2.68
Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A (2008) 2.57
An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum (2002) 2.54
Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology (2002) 2.41
Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation (2011) 2.35
Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat Med (2005) 2.31
An oligodendrocyte cell adhesion molecule at the site of assembly of the paranodal axo-glial junction. J Cell Biol (2000) 2.24
Treatment of autoimmune myasthenia gravis. Neurology (2003) 2.20
Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry (1985) 2.11
Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology (2011) 2.07
Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology (2004) 2.04
Neurofascin is a glial receptor for the paranodin/Caspr-contactin axonal complex at the axoglial junction. Curr Biol (2002) 1.94
Serial observations on patterns of growth, myelin formation, maintenance and degeneration in cultures of new-born rat and kitten cerebellum. J Biophys Biochem Cytol (1958) 1.94
A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J Immunol (1987) 1.92
T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis. Glia (2001) 1.91
Differentiation and death of premyelinating oligodendrocytes in developing rodent brain. J Cell Biol (1997) 1.89
Association of TAG-1 with Caspr2 is essential for the molecular organization of juxtaparanodal regions of myelinated fibers. J Cell Biol (2003) 1.79
Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 1.79
Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med (2007) 1.77
Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation. Ann Neurol (1999) 1.77
T and B cell responses to myelin-oligodendrocyte glycoprotein in multiple sclerosis. J Immunol (1991) 1.65
Sodium channel beta1 and beta3 subunits associate with neurofascin through their extracellular immunoglobulin-like domain. J Cell Biol (2001) 1.60
The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am J Pathol (1993) 1.59
Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol (2001) 1.58
Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis. Neurology (2004) 1.58
Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol (2009) 1.55
Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 1.53
Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol (2009) 1.50
THE APPLICATION OF TISSUE CULTURE TO THE STUDY OF EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS. II. SERUM FACTORS RESPONSIBLE FOR DEMYELINATION. J Exp Med (1964) 1.49
Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol (2011) 1.49
Paranodal interactions regulate expression of sodium channel subtypes and provide a diffusion barrier for the node of Ranvier. J Neurosci (2003) 1.47
Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc Natl Acad Sci U S A (2009) 1.26
Autoimmune disorders affecting both the central and peripheral nervous system. Autoimmun Rev (2011) 1.22
The in vitro demyelinating activity of sera from guinea pigs sensitized with whole CNS and with purified encephalitogen. Exp Neurol (1968) 1.21
The M2 autoantigen of central nervous system myelin, a glycoprotein present in oligodendrocyte membrane. Clin Exp Immunol (1986) 1.17
Prospects for B-cell-targeted therapy in autoimmune disease. Rheumatology (Oxford) (2004) 1.15
Ganglioside antibodies and neuropathies. Curr Opin Neurol (2008) 1.15
The role of antibodies in multiple sclerosis. Biochim Biophys Acta (2010) 1.12
Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls. J Neuroimmunol (1991) 1.11
Axo-glial antigens as targets in multiple sclerosis: implications for axonal and grey matter injury. J Mol Med (Berl) (2010) 1.11
Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children. Mult Scler (2010) 1.11
Antibody responses in chronic relapsing experimental allergic encephalomyelitis: correlation of serum demyelinating activity with antibody titre to the myelin/oligodendrocyte glycoprotein (MOG). J Neuroimmunol (1987) 1.08
Humoral autoimmunity in multiple sclerosis. J Neurol Sci (2010) 1.05
Pathogenetic role of autoantibodies in neurological diseases. Trends Neurosci (2000) 1.05
Astrocytes, but not olfactory ensheathing cells or Schwann cells, promote myelination of CNS axons in vitro. Glia (2008) 1.04
The fine specificity of the myelin oligodendrocyte glycoprotein autoantibody response in patients with multiple sclerosis and normal healthy controls. J Neuroimmunol (2001) 1.03
Immunoglobulins and complement in postmortem multiple sclerosis tissue. Ann Neurol (2009) 0.98
Myelinated, synapsing cultures of murine spinal cord--validation as an in vitro model of the central nervous system. Eur J Neurosci (2008) 0.98
Tissue culture studies of demyelinating disease: a critical review. Ann Neurol (1977) 0.94
Multiple sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein. Brain (1999) 0.93
Neuroelectric blocking factors in multiple sclerosis and normal human sera. Arch Neurol (1976) 0.92
Myelination inhibiting and neuroelectric blocking factors in experimental allergic encephalomyelitis. Science (1975) 0.91
Multiple sclerosis: serum gamma globulin and demyelination in organ culture. Neurology (1980) 0.91
Resistance is futile: antineuronal autoimmunity in multiple sclerosis. Trends Immunol (2008) 0.88
Antibodies to sulfatide in cerebrospinal fluid of patients with multiple sclerosis. J Neuroimmunol (2003) 0.87
Patients with active relapsing-remitting multiple sclerosis synthesize antibodies recognizing oligodendrocyte progenitor cell surface protein: implications for remyelination. Ann Neurol (2000) 0.87
Serum autoantibodies to cell surface determinants in multiple sclerosis: a flow cytometric study. Brain (2003) 0.86
Humoral factors involved in immune processes in multiple sclerosis and allergic encephalomyelitis. Br Med Bull (1977) 0.83
Autoantibodies and neurodegeneration in multiple sclerosis. Lab Invest (2008) 0.83
Plasma exchange for severe attacks of inflammatory demyelinating diseases of the central nervous system. J Clin Apher (2001) 0.80
The pathogenesis of primary progressive multiple sclerosis: antibody-mediated attack and no repair? J Clin Neurosci (2004) 0.79
Myelin flow cytometry assay detects enhanced levels of antibodies to human whole myelin in a subpopulation of multiple sclerosis patients. J Neuroimmunol (2006) 0.78
Meta-analysis of clinical studies of the efficacy of plasma exchange in the treatment of chronic progressive multiple sclerosis. J Clin Apher (1995) 0.77
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med (2003) 6.73
Progress and prospects in rat genetics: a community view. Nat Genet (2008) 6.01
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet (2007) 4.22
Astrocytes are active players in cerebral innate immunity. Trends Immunol (2007) 4.08
Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med (2012) 2.90
Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat Biotechnol (2003) 2.80
MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain (2009) 2.74
Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol (2008) 2.48
Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood (2011) 2.44
Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol (2010) 2.40
Preferential expression and function of Toll-like receptor 3 in human astrocytes. J Neuroimmunol (2004) 2.39
Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmun Rev (2010) 2.38
Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation (2011) 2.35
MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nat Genet (2005) 2.32
Latent herpesvirus infection in human trigeminal ganglia causes chronic immune response. Am J Pathol (2003) 2.24
Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis. Brain (2011) 2.24
Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry (2013) 2.23
B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol (2010) 2.17
Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain (2005) 2.17
Diagnosis and management of calcified carotid artery atheroma: dental perspectives. Oral Surg Oral Med Oral Pathol Oral Radiol (2012) 2.14
Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology (2012) 2.09
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology (2013) 2.02
Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med (2009) 2.02
Cerebrospinal fluid oligoclonal bands are important in the diagnosis of multiple sclerosis, unreasonably downplayed by the McDonald criteria 2010: Yes. Mult Scler (2013) 1.95
Management of postpolio syndrome. Lancet Neurol (2010) 1.94
Multiple sclerosis: T-cell receptor expression in distinct brain regions. Brain (2007) 1.94
BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med (2005) 1.92
Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig (2010) 1.91
The activation status of neuroantigen-specific T cells in the target organ determines the clinical outcome of autoimmune encephalomyelitis. J Exp Med (2004) 1.90
MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med (2013) 1.88
B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol (2012) 1.80
PTPN22 deficiency cooperates with the CD45 E613R allele to break tolerance on a non-autoimmune background. J Immunol (2009) 1.79
Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol (2013) 1.79
Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med (2007) 1.77
Neurological deficits caused by tissue hypoxia in neuroinflammatory disease. Ann Neurol (2013) 1.70
Characteristics of Susac syndrome: a review of all reported cases. Nat Rev Neurol (2013) 1.69
Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica. PLoS One (2010) 1.68
Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis. Neurology (2012) 1.67
High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women. Mult Scler (2012) 1.64
Shift work at young age is associated with increased risk for multiple sclerosis. Ann Neurol (2011) 1.63
Changes to anti-JCV antibody levels in a Swedish national MS cohort. J Neurol Neurosurg Psychiatry (2013) 1.63
Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med (2009) 1.63
Extracellular matrix in multiple sclerosis lesions: Fibrillar collagens, biglycan and decorin are upregulated and associated with infiltrating immune cells. Brain Pathol (2010) 1.61
Infectious causes of acute flaccid paralysis. Curr Opin Infect Dis (2003) 1.61
Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med (2007) 1.61
Low serum levels of vitamin D in idiopathic inflammatory myopathies. Ann Rheum Dis (2012) 1.59
Imatinib ameliorates neuroinflammation in a rat model of multiple sclerosis by enhancing blood-brain barrier integrity and by modulating the peripheral immune response. PLoS One (2013) 1.57
Fine-mapping the genetic association of the major histocompatibility complex in multiple sclerosis: HLA and non-HLA effects. PLoS Genet (2013) 1.55
Prior poliomyelitis-evidence of cytokine production in the central nervous system. J Neurol Sci (2002) 1.54
Neonatal vitamin D status and risk of multiple sclerosis. Ann Neurol (2014) 1.54
Interaction between adolescent obesity and HLA risk genes in the etiology of multiple sclerosis. Neurology (2014) 1.54
Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis. Neurology (2009) 1.51
The IBV Valve trial: a multicenter, randomized, double-blind trial of endobronchial therapy for severe emphysema. J Bronchology Interv Pulmonol (2014) 1.51
T-cell homeostasis in pediatric multiple sclerosis: old cells in young patients. Neurology (2013) 1.51
The Asthma-COPD Overlap Syndrome: A Common Clinical Problem in the Elderly. J Allergy (Cairo) (2011) 1.49
Neurofascin 186 specific autoantibodies induce axonal injury and exacerbate disease severity in experimental autoimmune encephalomyelitis. Exp Neurol (2013) 1.46
Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler (2010) 1.46
Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler (2012) 1.46
IL-33 attenuates EAE by suppressing IL-17 and IFN-γ production and inducing alternatively activated macrophages. Eur J Immunol (2012) 1.43
Lack of replication of interaction between EBNA1 IgG and smoking in risk for multiple sclerosis. Neurology (2012) 1.42
Low vitamin D and elevated immunoreactivity against Epstein-Barr virus before first clinical manifestation of multiple sclerosis. J Neurol Neurosurg Psychiatry (2012) 1.41
Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain (2004) 1.32
Targeting experimental autoimmune encephalomyelitis lesions to a predetermined axonal tract system allows for refined behavioral testing in an animal model of multiple sclerosis. Am J Pathol (2004) 1.31
Ro/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block. J Exp Med (2005) 1.31
Distinct responses of monocytes to Toll-like receptor ligands and inflammatory cytokines. Int Immunol (2004) 1.31
Combined sequence-based and genetic mapping analysis of complex traits in outbred rats. Nat Genet (2013) 1.30
Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol (2013) 1.30
Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases. J Immunol (2013) 1.27
Structural insights into the antigenicity of myelin oligodendrocyte glycoprotein. Proc Natl Acad Sci U S A (2003) 1.27
CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin. J Neuroinflammation (2005) 1.27
Progressive encephalomyelitis with rigidity and myoclonus: a new variant with DPPX antibodies. Neurology (2014) 1.26
Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc Natl Acad Sci U S A (2009) 1.26
Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Mult Scler (2013) 1.22
Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression. PLoS One (2013) 1.21
A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler (2011) 1.21
Lesion morphology at 7 Tesla MRI differentiates Susac syndrome from multiple sclerosis. Mult Scler (2012) 1.18
Cardiac hypertrophy in transgenic rats expressing a dominant-negative mutant of the natriuretic peptide receptor B. Proc Natl Acad Sci U S A (2006) 1.18
Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis. PLoS One (2013) 1.18
Positional mapping for amplified DNA sequences on 1q21-q22 in hepatocellular carcinoma indicates candidate genes over-expression. J Hepatol (2003) 1.17
Cortical demyelination is prominent in the murine cuprizone model and is strain-dependent. Am J Pathol (2008) 1.16
Lack of support for association between the KIF1B rs10492972[C] variant and multiple sclerosis. Nat Genet (2010) 1.16
Olfactory ensheathing cells induce less host astrocyte response and chondroitin sulphate proteoglycan expression than Schwann cells following transplantation into adult CNS white matter. Exp Neurol (2003) 1.16
Stimulation of the neurotrophin receptor TrkB on astrocytes drives nitric oxide production and neurodegeneration. J Exp Med (2012) 1.15
Temporal expression and cellular origin of CC chemokine receptors CCR1, CCR2 and CCR5 in the central nervous system: insight into mechanisms of MOG-induced EAE. J Neuroinflammation (2007) 1.15
A resource for the simultaneous high-resolution mapping of multiple quantitative trait loci in rats: the NIH heterogeneous stock. Genome Res (2008) 1.13
Mitochondrial haplogroup H correlates with ATP levels and age at onset in Huntington disease. J Mol Med (Berl) (2010) 1.13
Presence of HSV-1 immediate early genes and clonally expanded T-cells with a memory effector phenotype in human trigeminal ganglia. Brain Pathol (2007) 1.11
Axo-glial antigens as targets in multiple sclerosis: implications for axonal and grey matter injury. J Mol Med (Berl) (2010) 1.11